These days, a lot of his research is focused on PD-1/L1 mechanisms, TIGIT and dendritic cells in cancer immunology. Besides ...

The Second Indication of Ivonescimab in NSCLC 2L+ EGFRm NSCLC Already Approved in May 2024 HONG KONG, Aug. 14, 2024 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) ("Akeso,") today announced that the ...

PD-L1 is a cell ... with MSD’s PD-1 inhibitor Keytruda (pembrolizumab), a widely-used treatment for various cancers, including melanoma and non-small cell lung cancer (NSCLC), over six months.

Patients with NSCLC taking five or more medications tended to have worse survival, highlighting the need for medication ...

PD-1 checkpoints interrupt signals a T cell needs ... Activation helps T cells suppress tumors and other dangers. However, cancer cells are nebulous opponents. They can warp their appearance ...

Tumor immunotherapy leverages the body's immune system to target and eradicate cancer cells, offering a crucial treatment for patients unresponsive to surgery or conventional therapies. Despite its ...

Programmed death ligand 2, or PD-L2, is a checkpoint protein found on the surface of specific immune and cancer cells. As illustrated in Figure 1, this molecule is known to bind to PD-1 checkpoint ...

Progenitor exhausted CD8+ T (Tpex) cells have emerged as a pivotal component in tumor immunotherapy due to their unique ...

If approved, Zynyz could become the first PD-1/L1 antibody approved for first ... of patients with first-line metastatic non-small cell lung cancer in the phase 3 POD1UM-304 trial.

Jemperli in combination with chemotherapy showed a 31% reduction in the risk of death and a 16.4-month improvement in median ...

Durvalumab was also granted breakthrough therapy designation for the treatment of patients with limited-stage small cell lung cancer.